与磺酰脲类药物相比，二甲双胍与房颤和室性心律失常的风险降低相关：一项观察性研究。
Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas: An Observational Study.
机构信息
Department of Biomedical Informatics (A.O., G.H.), College of Physicians and Surgeons of Columbia University, NY.
Department of Medicine (P.A.E., M.V.R., E.Y.W., U.B.P., G.H., J.P.M.), College of Physicians and Surgeons of Columbia University, NY.
出版信息
Circ Arrhythm Electrophysiol. 2021 Mar;14(3):e009115. doi: 10.1161/CIRCEP.120.009115. Epub 2021 Feb 7.
Abstract
[Figure: see text].
摘要
[图：见正文]。
相似文献
1
Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas: An Observational Study.与磺酰脲类药物相比，二甲双胍与房颤和室性心律失常的风险降低相关：一项观察性研究。
Circ Arrhythm Electrophysiol. 2021 Mar;14(3):e009115. doi: 10.1161/CIRCEP.120.009115. Epub 2021 Feb 7.
2
Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.美国成年糖尿病患者的种族、族裔与噻唑烷二酮类药物的使用情况。
Curr Med Res Opin. 2007 Mar;23(3):489-94. doi: 10.1185/030079906X167354.
3
Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.老年人群在真实世界中接受口服降糖单药治疗时不良事件的评估：一项回顾性队列分析
Drugs Aging. 2008;25(7):611-22. doi: 10.2165/00002512-200825070-00006.
4
Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.磺酰脲类药物和二甲双胍联合治疗与 2 型糖尿病患者的死亡预防：一项巢式病例对照研究。
Pharmacoepidemiol Drug Saf. 2010 Apr;19(4):335-42. doi: 10.1002/pds.1834.
5
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).罗格列酮联合二甲双胍或磺脲类药物与二甲双胍/磺脲类药物联合治疗对2型糖尿病患者动态血压的影响：一项随机对照试验（RECORD研究）
Cardiovasc Diabetol. 2008 Apr 24;7:10. doi: 10.1186/1475-2840-7-10.
6
[Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].[口服抗糖尿病药物治疗——冠心病情况下的特殊考虑因素]
Dtsch Med Wochenschr. 2005 Apr 29;130(17):1091-6. doi: 10.1055/s-2005-866793.
7
The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.接受口服药物单一疗法治疗的2型糖尿病患者发生心力衰竭的风险。
Eur J Heart Fail. 2008 Jul;10(7):703-8. doi: 10.1016/j.ejheart.2008.05.013. Epub 2008 Jun 19.
8
Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes.
Diabetes Obes Metab. 2002 Sep;4(5):296-304. doi: 10.1046/j.1463-1326.2002.00189.x.
9
Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.噻唑烷二酮类药物和α-葡萄糖苷酶抑制剂作为二线口服降糖药联合二甲双胍治疗可降低 2 型糖尿病患者的心血管风险：一项全国性队列观察研究。
Cardiovasc Diabetol. 2018 Jan 24;17(1):20. doi: 10.1186/s12933-018-0663-6.
10
Progressing From Metformin to Sulfonylureas or Meglitinides.从二甲双胍转为磺酰脲类或米格列醇类药物。
Workplace Health Saf. 2016 Sep;64(9):433-9. doi: 10.1177/2165079916644263.
引用本文的文献
1
Multi-omics reveals mechanism of Qi-Po-Sheng-Mai granule in reducing atrial fibrillation susceptibility in aged rats.多组学揭示芪珀生脉颗粒降低老龄大鼠房颤易感性的机制。
Chin Med. 2025 Sep 3;20(1):118. doi: 10.1186/s13020-025-01154-6.
2
The Role of Early Risk Factor Modification and Ablation in Atrial Fibrillation Substrate Remodeling Prevention.早期危险因素修正及消融在预防心房颤动基质重塑中的作用
Biomedicines. 2025 Feb 7;13(2):405. doi: 10.3390/biomedicines13020405.
3
Upstream targeting for the prevention of atrial fibrillation: Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)-rationale and study design.预防心房颤动的上游靶向治疗：心房颤动的靶向风险干预与二甲双胍治疗（TRIM-AF）——原理与研究设计
J Interv Card Electrophysiol. 2025 Jan;68(1):9-19. doi: 10.1007/s10840-024-01955-z. Epub 2024 Dec 13.
4
Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics.2 型糖尿病心血管自主神经功能障碍发展过程中心内神经节重塑：分子机制与治疗。
Int J Mol Sci. 2024 Nov 20;25(22):12464. doi: 10.3390/ijms252212464.
5
Association of left atrial function with frailty: The Atherosclerosis Risk in Communities (ARIC) study.左心房功能与衰弱的关联：社区动脉粥样硬化风险（ARIC）研究
J Am Geriatr Soc. 2024 Dec;72(12):3810-3823. doi: 10.1111/jgs.19187. Epub 2024 Sep 13.
6
Effect of different hypoglycemic drugs and insulin on the risk of new-onset atrial fibrillation in people with diabetes: a network meta-analysis.不同降糖药物和胰岛素对糖尿病患者新发心房颤动风险的影响：一项网状Meta分析
Eur J Med Res. 2024 Jul 31;29(1):399. doi: 10.1186/s40001-024-01954-w.
7
Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights.曲格列汀治疗 2 型糖尿病的临床疗效及安全性评价
Vasc Health Risk Manag. 2024 Jun 21;20:255-288. doi: 10.2147/VHRM.S391808. eCollection 2024.
8
Antiarrhythmic effects of metformin.二甲双胍的抗心律失常作用。
Heart Rhythm O2. 2024 Apr 11;5(5):310-320. doi: 10.1016/j.hroo.2024.04.003. eCollection 2024 May.
9
Metformin reduces new-onset atrial fibrillation risk rather than atrial fibrillation burden in type 2 diabetes patients: A case-control study.二甲双胍降低2型糖尿病患者新发房颤风险而非房颤负荷：一项病例对照研究。
Heliyon. 2024 May 9;10(10):e30992. doi: 10.1016/j.heliyon.2024.e30992. eCollection 2024 May 30.
10
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications.心房颤动中的代谢重塑：表现、机制及临床意义。
Nat Rev Cardiol. 2024 Oct;21(10):682-700. doi: 10.1038/s41569-024-01038-6. Epub 2024 May 30.
本文引用的文献
1
How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.我们对医疗保健领域观察性研究结果的信心有多少：一项基准研究。
Harv Data Sci Rev. 2020;2(1). doi: 10.1162/99608f92.147cc28e. Epub 2020 Jan 31.
2
Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients.非糖尿病供体心脏移植到糖尿病受者后的脂质蓄积。
J Am Coll Cardiol. 2020 Mar 24;75(11):1249-1262. doi: 10.1016/j.jacc.2020.01.018.
3
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - .美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法的共识声明 -
Endocr Pract. 2020 Jan;26(1):107-139. doi: 10.4158/CS-2019-0472.
4
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.达格列净对 2 型糖尿病患者心房颤动的影响：来自 DECLARE-TIMI 58 试验的见解。
Circulation. 2020 Apr 14;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183. Epub 2020 Jan 27.
5
A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.二甲双胍与磺脲类药物在 2 型糖尿病合并慢性肾脏病患者中的起始安全性比较：一项回顾性队列研究。
Mayo Clin Proc. 2020 Jan;95(1):90-100. doi: 10.1016/j.mayocp.2019.07.017.
6
Introduction: .引言：.
Diabetes Care. 2020 Jan;43(Suppl 1):S1-S2. doi: 10.2337/dc20-Sint.
7
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.一线降压药类别全面比较效果和安全性：系统的、多国的、大规模分析。
Lancet. 2019 Nov 16;394(10211):1816-1826. doi: 10.1016/S0140-6736(19)32317-7. Epub 2019 Oct 24.
8
Dietary Saturated Fat Promotes Arrhythmia by Activating NOX2 (NADPH Oxidase 2).膳食饱和脂肪通过激活 NOX2（NADPH 氧化酶 2）促进心律失常。
Circ Arrhythm Electrophysiol. 2019 Nov;12(11):e007573. doi: 10.1161/CIRCEP.119.007573. Epub 2019 Oct 31.
9
Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway.二甲双胍通过 AMPK/PPAR-α/VLCAD 通路调节犬心房颤动模型中的脂质代谢。
Lipids Health Dis. 2019 May 10;18(1):109. doi: 10.1186/s12944-019-1059-7.
10
Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.血红蛋白 A1c 水平与二甲双胍治疗的 2 型糖尿病患者使用磺酰脲类、二肽基肽酶 4 抑制剂和噻唑烷二酮类药物的相关性：来自观察性健康数据科学和信息学倡议的分析。
JAMA Netw Open. 2018 Aug 3;1(4):e181755. doi: 10.1001/jamanetworkopen.2018.1755.
Zotero 插件